학술논문
A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma
Document Type
Article
Author
Source
In: Oncologist . (Oncologist, March 2017, 22(3):241-242 and e9-e15)
Subject
Language
English
ISSN
1549490X
10837159
10837159